Artelo Biosciences
ARTL
8 hedge funds and large institutions have $122K invested in Artelo Biosciences in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, reducing their positions, and 3 closing their positions.
271% more capital inflows, than outflows
Capital inflows: $147K | Capital outflows: $39.7K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
14% more funds holding
Funds holding: 7 → 8 (+1)
10.39% less ownership
Funds ownership: 15.91% → 5.52% (-10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$88.9K |
| 2 |
Jane Street
New York
|
+$32.6K |
| 3 |
Citigroup
New York
|
+$25K |
| 4 |
Altshuler Shaham
Tel Aviv,
Israel
|
+$776 |
| 5 |
Rothschild Investment LLC
Chicago,
Illinois
|
+$14 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$15.5K |
| 2 |
StoneX Group
New York
|
-$14.7K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$9.45K |
| 4 |
Danske Bank
Copenhagen K,
Denmark
|
-$1 |
ARTL Hedge Fund Activity: Q3 2026 in Review
8 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2026, worth a combined $122K — down 7.5% from $132K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ARTL positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $88.9K. The largest seller was Geode Capital Management, exiting entirely with an estimated $15.5K sold.
- 8 institutional investors held Artelo Biosciences (ARTL) as of Q3 2026, up from 7 in Q2 2026.
- Funds reported $122K of Artelo Biosciences stock for Q3 2026, down 7.5% quarter-over-quarter.
- 4 funds opened new Artelo Biosciences positions in Q3 2026 and 3 closed out, a net change of +1 holder.
- The largest Artelo Biosciences buyer in Q3 2026 was UBS Group, an estimated $88.9K added.
- The largest Artelo Biosciences seller in Q3 2026 was Geode Capital Management, an estimated $15.5K sold.
Based on aggregated 13F filings for Q3 2026.